Regulatory Strategy in the DACH Region: Success Factors

Introduction

The DACH region, with its three legal jurisdictions and different regulatory cultures, poses special challenges for life sciences companies. A well-thought-out regulatory strategy is the key to efficient market access.

1. EU Approval Procedures: Centralized vs. Decentralized

The choice of approval procedure has far-reaching consequences. The centralized procedure through the EMA is suitable for innovative drugs, while the decentralized or mutual recognition procedure is often more efficient for generic and biosimilar products.

2. Swiss Particularities

Switzerland is not an EU member and has its own approval procedures through Swissmedic. The Mutual Recognition Agreement (MRA) with the EU facilitates recognition, but requires separate regulatory strategies. New requirements apply following the 2024 MRA update.

3. Regulatory Interaction as a Strategic Tool

Early advisory meetings (Scientific Advice) with EMA, BfArM, AGES, or Swissmedic are not mandatory - but they are an enormous strategic advantage. They reduce regulatory risks and significantly accelerate approval processes.

4. MDR/IVDR: New Requirements for Medical Devices

The EU Medical Devices Regulation (MDR) has fundamentally increased regulatory requirements for medtech companies. Clinical evaluations, post-market surveillance, and Unique Device Identification (UDI) require new processes and competencies.

5. Pharmacovigilance Systems

A robust pharmacovigilance system is not only a regulatory obligation but also a competitive advantage. Automated signal detection, AI-powered case processing, and efficient QPPV structures are best practice.

Conclusion

Regulatory excellence is a differentiator. Companies that understand regulatory affairs as a strategic function - not as compliance overhead - achieve faster time-to-market and better market positions. CovaSyn supports you with deep regulatory know-how in the DACH region.